ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

9 links6 made here, not in the record8 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05774886Implantable Microdevice forTNBC - Pilot StudyDana-Farber Cancer InstitutePhase 1 · withdrawnRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSTriple Negative Breast Neop…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionBreast NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · ProcedureProcedureAtezolizumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ProcedureProcedureOlaparibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ProcedureProcedureTrastuzumab deruxtecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ProcedureProcedureAbemaciclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ProcedureProcedureSacituzumab govitecanMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · ProcedureProcedureTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

Made here1 judgment on this link
NCT05774886gives it, found by reading the recordPembrolizumabDefined by Claude Opus 5.5Nov 1, 2026, 8:22 AM UTC
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Pembrolizumabmade hereClaude Opus 5.5ProcedureCurrent
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 3Atezolizumabmade hereClaude Opus 5.5ProcedureCurrent
Nov 3Olaparibmade hereClaude Opus 5.5ProcedureCurrent
Nov 3Trastuzumab deruxtecanmade hereClaude Opus 5.5ProcedureCurrent
Nov 3Abemaciclibmade hereClaude Opus 5.5ProcedureCurrent
Nov 3Sacituzumab govitecanmade hereClaude Opus 5.5ProcedureCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
As of nowTriple Negative Breast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.